IRAK4-IN-17 (Compound 5) is a highly potent IRAK4 inhibitor with an IC50 value of 1.3 nM [1], and it is particularly valuable for research on large B-cell lymphoma (DLBCL) [1].

IRAK4-IN-17, at concentrations ranging from 0.7 to 40.1 μM over 72 hours, selectively inhibits OCI-LY10 and TMD8 cell lines harboring the MYD88 L265P mutation. At a lower concentration range of 0.3 to 10 μM for 2 hours, it targets the IRAK4 signaling pathway, reducing the viability of DLBCL (Diffuse Large B-Cell Lymphoma) cells. The compound exhibits varying cytotoxic effects, with IC50 values of 0.7 μM and 1.2 μM against OCI-LY10 and TMD8 cells, respectively, indicating its potent suppression capability, whereas it displays diminished effectiveness on Ramos and HT cell lines with wild-type MYD88, evidenced by IC50 values of 11.4 μM and 40.1 μM. Western Blot analysis further supports these findings by showing inhibition of IRAK4 phosphorylation and the downstream molecules, IKKβ and NF-κB transcription factor (p65), in OCI-LY10 and TMD8 cells, confirming the compound's targeted mechanistic action.